文献速递肝病

血小板反应蛋白-2是大型欧洲多中心队列中高危MASH和晚期MASH纤维化的高效生物标志物

Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort.
PubMed 文献 · Gut · 2026-05-12

该回顾性研究在三个欧洲中心纳入469例疑似MASLD且接受肝活检的患者,评估TSP2、IGFBP7、GDF15和CD163的诊断性能。TSP2对晚期纤维化(AF)和高危MASH(ARM)的AUROC均为0.812,优于其他生物标志物及多数对照指标;TSP2联合临床/生物学变量后AUROC分别升至0.846(AF)和0.845(ARM)。

要点

  • TSP2对AF的AUROC为0.812,高于其他生物标志物(0.680–0.769,p<0.001)。
  • TSP2对ARM的AUROC为0.812,高于其他生物标志物(0.722–0.748,p<0.001)。
  • TSP2联合AST、年龄、血小板、白蛋白、GGT后AF和ARM的AUROC分别达0.846和0.845。

核心结论

  • 血清TSP2单独或联合临床/生物学变量能有效区分MASLD患者的晚期纤维化和高危MASH。

研究设计与样本

  • 回顾性研究,来自三个欧洲中心,纳入因疑似MASLD接受肝活检的患者469例。
  • TSP2、IGFBP7、GDF15和CD163通过ELISA检测,对照指标包括VCTE、FIB4、Agile3和FAST评分。
  • 采用机器学习算法随机拆分总队列定义训练集和验证集,迭代100次,平均AUROC预测值。

主要发现

  • 纳入469例患者,男性61%,平均年龄51.4岁,BMI 30.6 kg/m²,2型糖尿病44%,高血压54%,晚期纤维化31%,高危MASH 46%。
  • TSP2对AF的AUROC为0.812(95% CI: 0.766–0.859),高于其他生物标志物(0.680–0.769,p<0.001),也高于VCTE(0.739,p<0.04)和FIB4(0.726,p<0.01)。
  • TSP2对ARM的AUROC为0.812(95% CI: 0.758–0.858),高于其他生物标志物(0.722–0.748,p<0.001)。
  • TSP2联合临床/生物学变量(AST、年龄、血小板、白蛋白、GGT)后,AF的AUROC升至0.846(95% CI: 0.807–0.885),ARM的AUROC升至0.845(95% CI: 0.806–0.880),显著优于所有其他生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-invasive biomarkers with biological rationale are needed for identifying patients with progressive metabolic dysfunction-associated steatohepatitis (MASH). OBJECTIVE: To test the diagnostic performance of thrombospondin-2 (TSP2), insulin-like growth factor binding protein-7 (IGFBP7), growth differentiation factor (GDF15) and CD163, which were identified by liver transcriptomics as associated with the severity of MASLD. DESIGN: Retrospective study from three European centres in patients with liver biopsy for suspected MASLD. TSP2, IGFBP7, GDF15 and CD163 were measured by ELISAs. Liver stiffness (vibration controlled transient elastography, VCTE), FIB4, Agile3 and FAST scores served as comparators. Outcomes were at-risk MASH (ARM, steatohepatitis NAS>4 and fibrosis stages 2-4) and advanced fibrosis (AF, stages 3-4). Combinatorial scores included fibrosis-biomarkers and clinical/biological variables using multivariate logistic regression controlling for centres, age, body mass index (BMI) and gender. Training and validation sets were defined using a machine learning algorithm with a random split of the total cohort, for 100 iterations, and averaging of area under the receiver operating characteristic curve (AUROC) predictions. RESULTS: 469 patients, 61% males, mean age 51.4 years, BMI 30.6 kg/m², 44% with type 2 diabetes, 54% with hypertension, 31% with AF and 46% with ARM were included. The TSP2 AUROC for AF was 0.812 (95% CI: 0.766 to 0.859) higher than for the other biomarkers (ranging from 0.680 to 0.769, p<0.001) and for the comparators (VCTE: 0.739, p<0.04; FIB4: 0.726, p<0.01 and Agile3: 0.755, p=0.20). The TSP2 AUROC for ARM was 0.812 (95% CI: 0.758 to 0.858) higher than for other biomarkers (ranging from 0.722 to 0.748, p<0.001) and comparators (FAST: 0.761, p=0.17). Combining TSP2 with clinical/biological variables (AST, age, platelets, albumin, GGT) increased AUROCs to 0.846 (95% CI: 0.807 to 0.885) for AF and 0.845 (95% CI: 0.806 to 0.880) for ARM and was significantly more performant than all other biomarkers. CONCLUSIONS: Serum TSP2, alone or with clinical/biological variables, potently discriminates AF and ARM in patients with MASLD.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ratziu V, Surabattula R, Bugianesi E, et al. Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort. Gut. 2026. PMID: 40738743. doi:10.1136/gutjnl-2025-335598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。